You are here: Industry Insights > Merck

News List

Merck sells consumer healthcare unit to P&G pharmatimes
July 16, 2018
Germany’s Merck is selling its consumer health unit to Procter & Gamble for around for 3.4 billion Euros.
Abcam, Merck Launch Anti-PD-L1 Antibody Clone contractpharma
July 03, 2018
Abcam announced the commercial launch of the new anti-PD-L1 antibody clone MKP1A07310 (clone 73-10) developed in collaboration with Merck KGaA, Darmstadt, Germany.
Merck and Novartis gender bias suits draw renewed attention, and New York is taking action fiercepharma
July 02, 2018
As the #MeToo movement puts workplace sexual harassment at the front, Merck & Co. and Novartis, two of the largest pharma companies, find themselves entangled in a different kind of gender problem: alleged pregnancy discrimination.
AstraZeneca, Merck eye $1 billion boost from cancer drug success financialexpress
June 29, 2018
The result should pave the way for expanded use of the medicine, which is being developed and marketed with Merck & Co under a deal struck last year
Merck to distribute HistoCyte Laboratories’ cell line products pharmaceutical-technology
June 28, 2018
Pharmaceutical company Merck has signed an agreement to become the exclusive multinational distributor of HistoCyte Laboratories’ portfolio of cell line reference products for immunohistochemistry and in situ hybridisation.
FDA Accepts sBLA for Merck’s Keytruda as Adjuvant Therapy in Advanced Melanoma americanpharmaceuticalreview
June 27, 2018
Merck announced the U.S. Food and Drug Administration (FDA) has accepted for standard review a new supplemental Biologics License Application (sBLA) for Keytruda, Merck’s anti-PD-1 therapy
10 years after a rejection, Merck returns to the FDA with a Gardasil 9 age expansion bid fiercevaccines
June 26, 2018
How long is a drugmaker willing to wait on an indication expansion plan? For Merck’s HPV vaccines, that's 10 years.
GlaxoSmithKline to pass $10B in 2024 vaccine sales, with Merck, Sanofi and Pfizer rounding out the top 4: report fiercevaccines
June 26, 2018
Shingrix may not make it on the top five best-selling vaccines list in 2024, but a diversified portfolio will still secure GlaxoSmithKline the lead position in the vaccine industry at that time, followed by Merck &Co.,
Merck impresses NICE with Keytruda data—and discounts—cueing up a CDF switch fiercepharma
June 11, 2018
England's cost watchdogs have recommended moving Merck's Keytruda off the Cancer Drugs Fund and making it available for routine use. (Merck)
How different are I-O stars from Merck, Roche and Bristol-Myers? Depends who you ask fiercepharma
June 07, 2018
It’s no secret that most ASCO watchers decided Merck's data on immuno-oncology star Keytruda would cement its position as king of the all-important lung cancer market.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page